Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
AssigneeAstra Aktiebolag
InventorsArne T. Eek, Sven Erik Sj ostrand
Life of this patent
Estimating the term…
Abstract
A synergistic pharmaceutical combination and composition are disclosed for the treatment of gastritis and peptic ulcer containing a therapeutic amount of a proton pump inhibitor such as e.g., omeprazole or lansoprazole, which increases intragastric pH, and a therapeutic amount of an acid degradable antibacterial compound such as a penicillin or a macrolide. In particular, the combination is directed to the treatment of infections caused by Helicobacter pylori by raising the bioavailability of acid degradable antibacterial compounds.
Claims19
A pharmaceutical composition for the treatment of gastritis and peptic ulcer comprising a therapeutically effective amount of a proton pump inhibitor which increases intragastric pH;
- and a therapeutically effective amount of an acid degradable antibacterial compound.
An oral pharmaceutical composition for the treatment of gastritis and peptic ulcer caused by Helicobacter pylori infections comprising as active ingredients
- (a) a therapeutically effective amount of a proton pump inhibiting compound which thereby increases the intragastric pH;
- and
- (b) a therapeutically effective amount of at least one acid degradable antibacterial compound.
A synergistic pharmaceutical combination of a therapeutic amount ranging from about 1-200 mg of proton pump inhibiting compound or salt thereof, which increases intragastric pH;
- and a therapeutic amount ranging from about 250 mg to 10g of an acid degradable antibacterial compound for the treatment of gastritis and peptic ulcer.
A synergistic pharmaceutical combination comprising a therapeutic amount of omeprazole or salt thereof and a therapeutic amount of a erythromycin for the treatment of gastritis and peptic ulcer.
A synergistic pharmaceutical combination comprising a therapeutic amount of omeprazole or salt thereof and a therapeutic amount of an acid degradable penicillin for the treatment of gastritis and peptic ulcer.
A synergistic pharmaceutical combination comprising therapeutic amount of omeprazole or salt thereof and a therapeutic amount of benzylpenicillin for the treatment of gastritis and peptic ulcer.
A synergistic pharmaceutical combination comprising a therapeutic amount of lansoprazole or salt thereof and a therapeutic amount of an erythromycin for the treatment of gastritis and peptic ulcer.
A synergistic pharmaceutical combination comprising a therapeutic amount of lansoprazole or salt thereof and a therapeutic amount of clarithromycin for the treatment of gastritis and peptic ulcer.
A synergistic pharmaceutical combination comprising a therapeutic amount of lansoprazole or salt thereof and a therapeutic amount of a penicillin for the treatment of gastritis and peptic ulcer.
A method for treatment of gastritis and peptic ulcer caused by Helicobacter pylori comprising first orally administering to a patient suffering therefrom a therapeutically effective amount of a composition comprising a proton pump inhibiting compound which is an inhibitor of gastric acid secretion;
- and thereafter or concomitantly administering a therapeutically effective amount of an acid degradable antibacterial compound.
Dependencies are inferred from the claim text.